COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

This phase II/III trial studies the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer. Duloxetine increases the amount of certain chemicals in the brain that help relieve depression and pain. Giving duloxetine in patients undergoing treatment with oxaliplatin for colorectal cancer may help prevent peripheral neuropathy.

Research Base: Alliance for Clinical Trials in Oncology
NCT ID: NCT04137107
NCI Protocol Number: A221805
Status: Recruiting

For more information see



Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8

Trial Type

Supportive Care/Symptom Management/PROs

See a list of participating sites on